NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
 
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
 
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.